Is Evolus Stock a Good Investment?
Evolus Investment Advice | EOLS |
- Examine Evolus' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Evolus' leadership team and their track record. Good management can help Evolus navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Pharmaceuticals space and any emerging trends that could impact Evolus' business and its evolving consumer preferences.
- Compare Evolus' performance and market position to its competitors. Analyze how Evolus is positioned in terms of product offerings, innovation, and market share.
- Check if Evolus pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Evolus' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Evolus Inc stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Evolus Inc is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Slowly supersedes the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Inapplicable | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Evolus Stock
Researching Evolus' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 12.0% of the company shares are held by company insiders. The company recorded a loss per share of 0.9. Evolus Inc had not issued any dividends in recent years.
To determine if Evolus is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Evolus' research are outlined below:
| Evolus Inc appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 202.09 M. Net Loss for the year was (61.69 M) with profit before overhead, payroll, taxes, and interest of 92.73 M. | |
| Evolus Inc currently holds about 84.48 M in cash with (34.01 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.51. | |
| Over 82.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from gurufocus.com: TANG CAPITAL MANAGEMENT LLC Acquires New Stake in Kezar Life Sciences Inc |
Evolus Quarterly Accounts Payable |
|
Evolus uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Evolus Inc. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Evolus' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 13th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Evolus' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Evolus' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-07-31 | 2024-06-30 | -0.05 | -0.04 | 0.01 | 20 | ||
2024-05-07 | 2024-03-31 | -0.1 | -0.09 | 0.01 | 10 | ||
2022-03-03 | 2021-12-31 | -0.19 | -0.22 | -0.03 | 15 | ||
2022-08-02 | 2022-06-30 | -0.24 | -0.28 | -0.04 | 16 | ||
2024-03-07 | 2023-12-31 | -0.07 | -0.12 | -0.05 | 71 | ||
2021-08-04 | 2021-06-30 | -0.24 | -0.19 | 0.05 | 20 | ||
2018-08-02 | 2018-06-30 | -0.29 | -0.34 | -0.05 | 17 | ||
2018-05-10 | 2018-03-31 | -0.24 | -0.3 | -0.06 | 25 |
Evolus Target Price Consensus
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Evolus target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Evolus' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 7 | Strong Buy |
Most Evolus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Evolus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Evolus Inc, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationEvolus Target Price Projection
Evolus' current and average target prices are 16.50 and 20.25, respectively. The current price of Evolus is the price at which Evolus Inc is currently trading. On the other hand, Evolus' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Target Price
Analyst Consensus On Evolus Target Price
Evolus Analyst Ratings
Evolus' analyst stock recommendations are determined by taking an average estimate of all analysts we track and classifying them as Strong Buy, Buy, Hold, Strong Sell, or Sell. Ratings generally communicate what analysts sense about Evolus stock, and they use a lot of effort and time to analyze it and arrive at a rating. That suggests that analyst recommendations are the outcome of an objective and thorough examination of Evolus' financials, market performance, and future outlook by experienced professionals. Evolus' historical ratings below, therefore, can serve as a valuable tool for investors.Know Evolus' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Evolus is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Evolus Inc backward and forwards among themselves. Evolus' institutional investor refers to the entity that pools money to purchase Evolus' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Geode Capital Management, Llc | 2024-06-30 | 1.2 M | Soleus Capital Management, L.p. | 2024-06-30 | 1.2 M | Boothbay Fund Management, Llc | 2024-06-30 | 996.5 K | Schroder Investment Management Group | 2024-06-30 | 977.6 K | Assenagon Asset Management Sa | 2024-06-30 | 947.1 K | Millennium Management Llc | 2024-06-30 | 899.4 K | D. E. Shaw & Co Lp | 2024-06-30 | 871.1 K | Rice Hall James & Associates, Llc | 2024-06-30 | 851.3 K | Soros Fund Management Llc | 2024-06-30 | 850 K | Nantahala Capital Management, Llc | 2024-06-30 | 5.8 M | Perceptive Advisors Llc | 2024-06-30 | 5.8 M |
Evolus' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.04 B.Market Cap |
|
Evolus' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.51) | (0.54) | |
| Return On Capital Employed | (0.26) | (0.27) | |
| Return On Assets | (0.33) | (0.34) | |
| Return On Equity | 2.98 | 3.13 |
Determining Evolus' profitability involves analyzing its financial statements and using various financial metrics to determine if Evolus is a good buy. For example, gross profit margin measures Evolus' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Evolus' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in Evolus' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Evolus Inc. Check Evolus' Beneish M Score to see the likelihood of Evolus' management manipulating its earnings.
Evaluate Evolus' management efficiency
Evolus Inc has return on total asset (ROA) of (0.0936) % which means that it has lost $0.0936 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (8.6168) %, meaning that it created substantial loss on money invested by shareholders. Evolus' management efficiency ratios could be used to measure how well Evolus manages its routine affairs as well as how well it operates its assets and liabilities. Return On Equity is likely to gain to 3.13 in 2024, whereas Return On Tangible Assets are likely to drop (0.54) in 2024. At this time, Evolus' Total Assets are comparatively stable compared to the past year. Intangibles To Total Assets is likely to gain to 0.57 in 2024, whereas Non Current Assets Total are likely to drop slightly above 63.4 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (0.36) | (0.35) | |
| Tangible Book Value Per Share | (1.56) | (1.64) | |
| Enterprise Value Over EBITDA | (21.93) | (20.83) | |
| Price Book Value Ratio | (28.97) | (27.52) | |
| Enterprise Value Multiple | (21.93) | (20.83) | |
| Price Fair Value | (28.97) | (27.52) | |
| Enterprise Value | 663.1 M | 696.2 M |
The analysis of Evolus' management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Evolus' future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Evolus Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Beta 1.314 |
Basic technical analysis of Evolus Stock
As of the 9th of October, Evolus shows the Coefficient Of Variation of 476.98, downside deviation of 2.45, and Mean Deviation of 2.13. Evolus Inc technical analysis allows you to utilize historical prices and volume patterns in order to determine a pattern that computes the direction of the firm's future prices. Please confirm Evolus Inc coefficient of variation, treynor ratio, as well as the relationship between the Treynor Ratio and semi variance to decide if Evolus Inc is priced favorably, providing market reflects its regular price of 16.5 per share. Given that Evolus has jensen alpha of 0.6001, we urge you to verify Evolus Inc's prevailing market performance to make sure the company can sustain itself at a future point.Evolus' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Evolus insiders, such as employees or executives, is commonly permitted as long as it does not rely on Evolus' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Evolus insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Understand Evolus' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Evolus' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1799 | |||
| Market Risk Adjusted Performance | 1.6 | |||
| Mean Deviation | 2.13 | |||
| Semi Deviation | 1.96 | |||
| Downside Deviation | 2.45 | |||
| Coefficient Of Variation | 476.98 | |||
| Standard Deviation | 3.09 | |||
| Variance | 9.56 | |||
| Information Ratio | 0.1756 | |||
| Jensen Alpha | 0.6001 | |||
| Total Risk Alpha | 0.2805 | |||
| Sortino Ratio | 0.2219 | |||
| Treynor Ratio | 1.59 | |||
| Maximum Drawdown | 19.21 | |||
| Value At Risk | (3.97) | |||
| Potential Upside | 6.26 | |||
| Downside Variance | 5.99 | |||
| Semi Variance | 3.83 | |||
| Expected Short fall | (2.45) | |||
| Skewness | 1.15 | |||
| Kurtosis | 3.4 |
| Risk Adjusted Performance | 0.1799 | |||
| Market Risk Adjusted Performance | 1.6 | |||
| Mean Deviation | 2.13 | |||
| Semi Deviation | 1.96 | |||
| Downside Deviation | 2.45 | |||
| Coefficient Of Variation | 476.98 | |||
| Standard Deviation | 3.09 | |||
| Variance | 9.56 | |||
| Information Ratio | 0.1756 | |||
| Jensen Alpha | 0.6001 | |||
| Total Risk Alpha | 0.2805 | |||
| Sortino Ratio | 0.2219 | |||
| Treynor Ratio | 1.59 | |||
| Maximum Drawdown | 19.21 | |||
| Value At Risk | (3.97) | |||
| Potential Upside | 6.26 | |||
| Downside Variance | 5.99 | |||
| Semi Variance | 3.83 | |||
| Expected Short fall | (2.45) | |||
| Skewness | 1.15 | |||
| Kurtosis | 3.4 |
Consider Evolus' intraday indicators
Evolus intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Evolus stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Evolus Corporate Filings
F4 | 6th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 31st of July 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 3rd of July 2024 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 26th of April 2024 Other Reports | ViewVerify |
Evolus Stock media impact
Far too much social signal, news, headlines, and media speculation about Evolus that are available to investors today. That information is available publicly through Evolus media outlets and privately through word of mouth or via Evolus internal channels. However, regardless of the origin, that massive amount of Evolus data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Evolus news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Evolus relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Evolus' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Evolus alpha.
Evolus Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Evolus can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Evolus Corporate Management
| Jessica Novak | Senior Resources | Profile | |
| Tomoko YamagishiDressler | Chief Officer | Profile | |
| CCFP DipSportMed | Chief RD | Profile | |
| David Erickson | VP Relations | Profile |
Additional Tools for Evolus Stock Analysis
When running Evolus' price analysis, check to measure Evolus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Evolus is operating at the current time. Most of Evolus' value examination focuses on studying past and present price action to predict the probability of Evolus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Evolus' price. Additionally, you may evaluate how the addition of Evolus to your portfolios can decrease your overall portfolio volatility.